SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Man holding a Chapter 11 bankruptcy filing
Deals
Athersys Adds to Surge of Biotechs Filing for Bankruptcy, Sells to Healios
All assets of the regenerative medicine and cell therapy company are being divested to its research partner to the tune of $2 million in the form of a credit bid.
January 9, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Man leaning against wall/iStock, Katarzy
Drug Development
Phase III Schizophrenia Trial Shows Lyndra’s Weekly Risperidone ‘Comparable’ to J&J’s Daily Risperdal
The late-stage pharmacokinetic study was stopped early due to efficacy at interim analysis, Lyndra Therapeutics said Thursday. A six-month safety study will start in the second half of 2024.
January 4, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Visualization of genetic phenotypes over
Drug Development
The Era of Precision Obesity Medicine Is Here
While GLP-1 drugs have exploded in popularity, they don’t work for everyone, and experts say phenotyping based on a greater understanding of the disease is the future of obesity treatment.
January 3, 2024
 · 
4 min read
 · 
Kate Goodwin
Pictured: Hundred dollar bills/iStock_Nattakorn Ma
Goldman Sachs Closes First Life Sciences VC Fund with $650M in Equity
The money will be funneled into early- to mid-stage therapeutic companies with “multi-asset portfolios” for the “next generation” of biotechs in addition to diagnostic and life sciences tools.
January 3, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: 3D concept art showing a bladder surrounded by cancer cells
ImmunityBio Snags $320M Royalty Deal Ahead of FDA Decision in April
Trading cash for single-digit royalties on products, the deal provides ImmunityBio with the cash it’ll need to potentially commercialize its bladder cancer drug, if approved. The PDUFA date is April 23, 2024.
January 2, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Doorway at the FTC building in Washingto
Policy
Three Companies Relent to FTC Demands, Delist Patents from FDA’s Orange Book
GSK withdrew three patents related to its asthma inhalers while Impax delisted both of its patents for Adrenaclick and Kaléo delisted eight patents covering Auvi-Q—the companies’ respective epinephrine auto-injectors.
December 22, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Rejected stamp/iStock, Pavel Muravev
Policy
FDA Denies Accelerated Approval for Clene’s ALS Candidate
Clene disclosed Thursday the FDA has determined that biomarker Neurofilament Light Chain reduction in its Phase II programs “were insufficient to support accelerated approval at this time.”
December 21, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Psilocybin science and research/iStock,
Drug Development
Compass Pathways’ Psilocybin Treatment ‘Well-Tolerated’ in Phase II PTSD Trial
The biotech’s investigational COMP360 psilocybin treatment showed positive safety and tolerability with no serious adverse events in a mid-stage study of people with post-traumatic stress disorder.
December 20, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Building with an Illumina sign in front/
Policy
Activist Investor Icahn Targets Illumina Board Amid GRAIL Divestiture
Carl Icahn is seeking to get rid of “legacy conflicted directors” on Illumina’s board following the announcement that GRAIL will be divested after a drawn out antitrust battle with regulators.
December 19, 2023
 · 
2 min read
 · 
Kate Goodwin
The EMA's former headquarters in London
Policy
Vertex-CRISPR’s Casgevy Gets Positive EMA Panel Opinion, Approval Decision in Q1 2024
A week after securing FDA approval, a European Medicines Agency committee has endorsed Vertex and CRISPR Therapeutics’ Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia.
December 15, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: White House/
Policy
White House Hits Pharma Again, Requires Rebates Over Drug ‘Price Gouging’
The Biden administration on Thursday said 48 drugs covered under Medicare’s Part B may be subject to inflation rebates in the first quarter of 2024 under the Inflation Reduction Act.
December 14, 2023
 · 
2 min read
 · 
Kate Goodwin
An IV bag circled by money, blood cells, and celeb
Both Autologous and Allogeneic Have a Place as Cell Therapy Market Explodes
As CAR T cell therapies attract significant biopharma investment, experts say there is plenty of space in the growing market for both treatments that use patients’ own cells and for those that rely on donor cells.
December 12, 2023
 · 
6 min read
 · 
Kate Goodwin
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Drug Development
BMS, 2seventy bio Present Abecma Survival Data at ASH Ahead of Adcomm
The FDA decided last month to convene an advisory committee to discuss the companies’ proposed use of Abecma in earlier lines of treatment for multiple myeloma. Data presented Monday at the American Society of Hematology annual meeting provides a clue as to why.
December 12, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Illustration of antibodies attacking a nerve cell
ASH 23: CAR-T for Autoimmune, Arcellx’s Multiple Myeloma Challenger and Seagen’s Combo Play
A CAR-T cell therapy for autoimmune diseases generated significant attention at the 2023 American Society of Hematology (ASH) annual meeting and Arcellx and Seagen posted promising data.
December 11, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Stack of coins with trading graph/iStock
Drug Development
Rebranded Spyre Therapeutics Secures $180M to Advance IBD Antibody Pipeline
The private placement from existing and new investors extends the company’s cash runway into the second half of 2026 and will help take two candidates for inflammatory bowel disease into the clinic in 2024.
December 8, 2023
 · 
1 min read
 · 
Kate Goodwin
Load More